Media coverage about Medtronic (NYSE:MDT) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medtronic earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical technology company an impact score of 47.0132966947678 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern’s scoring:
Several analysts have recently commented on the stock. Morgan Stanley raised their target price on shares of Medtronic from $91.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Monday, February 5th. Oppenheimer restated a “buy” rating and issued a $94.00 target price on shares of Medtronic in a research note on Tuesday, February 20th. TheStreet cut shares of Medtronic from a “b” rating to a “c+” rating in a research note on Tuesday, February 20th. Bank of America upgraded shares of Medtronic from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 2nd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $92.00 target price on shares of Medtronic in a research note on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have issued a buy rating to the stock. Medtronic currently has a consensus rating of “Buy” and an average target price of $91.24.
Shares of MDT traded down $0.10 during trading hours on Friday, reaching $79.90. The company had a trading volume of 3,690,928 shares, compared to its average volume of 4,645,961. The company has a quick ratio of 2.09, a current ratio of 2.43 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $108,294.30, a PE ratio of 17.37, a P/E/G ratio of 2.38 and a beta of 0.94. Medtronic has a 12-month low of $76.41 and a 12-month high of $89.72.
Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 20th. The medical technology company reported $1.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.01. The business had revenue of $7.37 billion during the quarter, compared to the consensus estimate of $7.20 billion. Medtronic had a net margin of 9.44% and a return on equity of 12.65%. The business’s revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.12 EPS. research analysts anticipate that Medtronic will post 4.74 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, April 13th. Stockholders of record on Friday, March 23rd were issued a $0.46 dividend. The ex-dividend date was Thursday, March 22nd. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.30%. Medtronic’s dividend payout ratio is presently 40.00%.
In other Medtronic news, Director James T. Lenehan sold 1,306 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $83.56, for a total transaction of $109,129.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Carol A. Surface sold 24,479 shares of the firm’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $78.18, for a total transaction of $1,913,768.22. The disclosure for this sale can be found here. Company insiders own 0.31% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/22/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-medtronic-mdt-share-price.html.
Medtronic Company Profile
Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.